Uniqure NV
QURE13.490USD
-0.205-1.50%
시장 운영 시간 （ET）시세는 15분 지연됩니다
740.12M시가총액
손실P/E TTM
자세한 내용은 Uniqure NV 회사
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
회사 정보
종목 코드 QURE
회사 이름Uniqure NV
상장일Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
직원 수209
유형Ordinary Share
회계 연도 종료Feb 05
주소Paasheuvelweg 25a
도시AMSTERDAM
증권 거래소NASDAQ Global Select Consolidated
국가Netherlands
우편 번호1105 BP
전화31202406000
웹사이트https://www.uniqure.com/
종목 코드 QURE
상장일Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jul 2
마지막 업데이트: Wed, Jul 2
주주
주주 유형
주주
주주
비율
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
주주
주주
비율
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
47.15%
Hedge Fund
23.24%
Investment Advisor
15.35%
Corporation
4.36%
Research Firm
3.09%
Venture Capital
2.58%
Individual Investor
1.72%
Private Equity
0.84%
Bank and Trust
0.06%
Other
1.60%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
394
54.93M
100.44%
-2.00M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
2023Q1
454
47.06M
99.04%
-12.29M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Vestal Point Capital, LP
4.79M
8.75%
+1.77M
+58.43%
Mar 31, 2025
RTW Investments L.P.
4.27M
7.79%
+3.36M
+372.04%
Mar 31, 2025
EcoR1 Capital, LLC
3.99M
7.29%
+588.97K
+17.32%
Mar 31, 2025
Nantahala Capital Management, LLC
2.76M
5.03%
+302.60K
+12.33%
Mar 31, 2025
abrdn Inc.
2.22M
4.05%
+706.22K
+46.79%
Mar 31, 2025
Bristol Myers Squibb
2.39M
4.36%
--
--
Sep 30, 2024
Avoro Capital Advisors LLC
2.17M
3.97%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.99M
3.63%
--
--
Mar 31, 2025
Two Sigma Investments, LP
1.58M
2.9%
-50.79K
-3.10%
Mar 31, 2025
683 Capital Management LLC
1.55M
2.83%
+25.00K
+1.64%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco Dorsey Wright Healthcare Momentum ETF
1.53%
WisdomTree BioRevolution Fund
1.09%
Global X Genomics & Biotechnology ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Main Thematic Innovation ETF
0.46%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
더 보기
Invesco Dorsey Wright Healthcare Momentum ETF
비율1.53%
WisdomTree BioRevolution Fund
비율1.09%
Global X Genomics & Biotechnology ETF
비율0.88%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.78%
Main Thematic Innovation ETF
비율0.46%
Invesco NASDAQ Future Gen 200 ETF
비율0.43%
SPDR S&P Biotech ETF
비율0.24%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.14%
Invesco Nasdaq Biotechnology ETF
비율0.09%
ProShares Ultra Nasdaq Biotechnology
비율0.09%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
